Advances in kinase targeting: current clinical use and clinical trials.
about
Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious DiseasesThe Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network PerspectiveDecoding the Interactions Regulating the Active State Mechanics of Eukaryotic Protein KinasesScreening and identification of novel biologically active natural compounds.Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells.Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinomeDetermining Cysteines Available for Covalent Inhibition Across the Human Kinome.Mitochondrial DNA somatic mutation in cancerCovalent-Allosteric Kinase Inhibitors.Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and MetastasiscJun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66Shc activationSearch for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model.UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.The Snf1-activating kinase Sak1 is a key regulator of metabolic adaptation and in vivo fitness of Candida albicans.A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects.Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts.From the research laboratory to the database: the Caenorhabditis elegans kinome in UniProtKBKinase inhibitors as potential agents in the treatment of multiple myeloma.Hedgehog inhibitors: a patent review (2013 - present).Masitinib for the treatment of mild to moderate Alzheimer's disease.Re-positioning protein-kinase inhibitors against schistosomiasis.A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.Lighting Up T Lymphocyte Signaling with Quantitative Phosphoproteomics.Diverse Molecular Targets for Chalcones with Varied Bioactivities.Multitarget Drugs: an Epigenetic Epiphany.Gastric cancer management: Kinases as a target therapy.Kinase targets in CNS drug discovery.Integration of phytochemicals and phytotherapy into cancer precision medicine.Principles of Kinase Inhibitor Therapy for Solid Tumors.Innovative computer-aided methods for the discovery of new kinase ligands.Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies.Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks.Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.Phosphorylation, Signaling, and Cancer: Targets and Targeting.Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer.Strategies to target the Hedgehog signaling pathway for cancer therapy.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
P2860
Q28081001-2DB8A683-AD26-48FB-BEFB-2D43AD0297CEQ28553277-5E4372FE-4BEC-4550-B409-35DB9DD6E3C7Q28554596-6B537DD1-2295-4DAB-B08E-A0BAEEF75AF1Q33777835-9A58B908-8BBD-44B6-BB9D-C8D7C5112F98Q33796957-4332F140-712C-41BE-8E7F-3C5B7463B2E3Q33811883-69CFBA7F-0097-4D23-8C04-AA79E967DC05Q33859476-78CEF9E7-74D1-47ED-AA16-0F801A82DF7BQ34906440-5C0B1E13-05B2-4F79-9DED-0F2CFC25B396Q35674207-532178CF-9EFD-4642-9A44-C4EE3DF28FA7Q35804400-1C2E325F-8746-4288-8CB9-F85EBED462AFQ35921419-B94C752E-9688-4C9C-9C23-AA7462E1DA83Q35992573-248F9669-6FC7-472B-BE7A-B0F09E5AB408Q36088545-AC0FAA4B-90FA-4834-8B92-9D29603909E0Q36321573-35E38D4B-4895-4E08-8114-963FACD45408Q37063651-C16E3783-2CC9-40B5-BC2C-98B617F78473Q37204806-6A8C8BA2-1AB8-483A-9621-687E46439698Q37622786-526D22ED-8B91-474C-A551-53B1BB5A3309Q37697253-E9371909-65D0-4D68-93FB-0A8265389BD5Q38366266-9C3CDCDD-3416-48D9-9B02-39175016C5CFQ38472067-7FF9FB5B-E600-43E2-9AED-9E68C79DFE62Q38495042-1381FB9C-95D8-4A39-941A-7A26796CF776Q38503202-1916B969-73BE-420E-B5AC-B7D84E105B37Q38604840-B86F6C22-79AA-4D51-9729-09558053EE77Q38707609-00E89A27-A476-4F55-8991-EE01E8D511BFQ38739347-0766EA43-7E5F-4A6D-B840-A99D0F3F570FQ38749038-77EB3D3B-BC6E-4A7B-A604-B17E27A91E40Q38760031-69729FA6-0FA8-48D6-B23D-40118EEC5C98Q38780465-B3053D8D-D58B-4CBA-A781-93A6062591D5Q38802154-220D2209-49A1-46D6-AA2E-26AAA2934C52Q38814898-34562626-DDE4-4246-B7DF-FBC5EEE1B234Q38910326-114F97B1-B5BE-42B7-AA16-0B10EA89BB43Q38930166-978629AC-50EA-4CAC-BC66-E30775C81B2EQ39020753-B8CBBE69-78AD-4A76-8BD3-B1A9F90B7F49Q41811693-3E4591B6-73B6-41B0-B910-2FBE612FDB8CQ42195551-B70D0703-CACC-49FD-B59F-CFD652FA3111Q42697768-E2AF6B7D-9494-4913-8931-6BA0CF00CA0DQ43189953-CE735F36-C18B-42F8-8301-4B8ED5B81B92Q45070681-4AC83EA6-3DA7-4224-8B09-8949DAFCD729Q47218042-4EE7E17C-D571-4EB5-A978-66DF22AE603EQ47439880-29DF995D-4FA1-4363-A272-45DCB77806B7
P2860
Advances in kinase targeting: current clinical use and clinical trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Advances in kinase targeting: current clinical use and clinical trials.
@ast
Advances in kinase targeting: current clinical use and clinical trials.
@en
type
label
Advances in kinase targeting: current clinical use and clinical trials.
@ast
Advances in kinase targeting: current clinical use and clinical trials.
@en
prefLabel
Advances in kinase targeting: current clinical use and clinical trials.
@ast
Advances in kinase targeting: current clinical use and clinical trials.
@en
P2093
P1476
Advances in kinase targeting: current clinical use and clinical trials.
@en
P2093
Doriano Fabbro
Mathias Rask-Andersen
P304
P356
10.1016/J.TIPS.2014.09.007
P577
2014-10-10T00:00:00Z